Payment overview · 2025
General Payments
$84.92
5 reported records · 4 companies
Healthcare provider profile · identity verified
Curry Jones, D.O
Allopathic & Osteopathic Physicians|Family Medicine · MARSHALL, NC · NPI 1720442668
Verified facts
What the public records show
CMS Open Payments records show Curry Jones, D.O received $84.92 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.03 | 47.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.69 | 18.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.00 | 17.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.20 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.92 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 203 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
203 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 103 |
| Lisinopril | Lisinopril | 422 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 85 |
| Losartan Potassium | Losartan Potassium | 334 | 82 |
| Omeprazole | Omeprazole | 296 | 83 |
| Gabapentin | Gabapentin | 278 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 66 |
| Metformin Hcl Er | Metformin Hcl | 206 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 64 |
| Ozempic | Semaglutide | 203 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 52 |
| Furosemide | Furosemide | 180 | 60 |
| Trazodone Hcl | Trazodone Hcl | 174 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 45 |
| Famotidine | Famotidine | 167 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 53 |
| Meloxicam | Meloxicam | 163 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 38 |
| Alprazolam | Alprazolam | 123 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 29 |
| Montelukast Sodium | Montelukast Sodium | 119 | 24 |
| Potassium Chloride | Potassium Chloride | 118 | 24 |
| Sertraline Hcl | Sertraline Hcl | 117 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 25 |
| Lorazepam | Lorazepam | 102 | 26 |
| Metformin Hcl | Metformin Hcl | 96 | 24 |
| Eliquis | Apixaban | 94 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 14 |
| Allopurinol | Allopurinol | 91 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 23 |
| Prednisone | Prednisone | 84 | 67 |
| Jardiance | Empagliflozin | 81 | 21 |
| Simvastatin | Simvastatin | 81 | 22 |
| Mirtazapine | Mirtazapine | 80 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 15 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 12 |
| Pregabalin | Pregabalin | 65 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 18 |
| Tramadol Hcl | Tramadol Hcl | 62 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 53 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Xarelto | Rivaroxaban | 52 | 18 |
| Clonazepam | Clonazepam | 51 | 16 |
| Glipizide Er | Glipizide | 51 | 11 |
| Baclofen | Baclofen | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Diazepam | Diazepam | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | 12 |
| Carvedilol | Carvedilol | 47 | 12 |
| Chlorthalidone | Chlorthalidone | 46 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 14 |
| Spironolactone | Spironolactone | 41 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 32 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 11 |
| Torsemide | Torsemide | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | 16 |
| Finasteride | Finasteride | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Fluconazole | Fluconazole | 26 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 17 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $84.92 · 5 records | Novo Nordisk Inc | BREZTRI, COMIRNATY, Ozempic, PREVNAR 20, Rybelsus, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error